Diapo 20aquilon6
Doc1

Aquilon Pharmaceuticals S.A.

Aquilon is a specialty pharmaceutical company engaged in the development of drugs & improving the treatment of pulmonary diseases using the "Biobetter" model

Company Summary

The Company focuses on the early steps of drug development.
It identifies, evaluates and licenses in promising academic projects in the pulmonary field.
It then uses its translational expertise to consolidate the pharmaceutical, pre-clinical, toxicological, clinical and intellectual property packages, so as to increase the value and license out the developed and matured product(s).

Team

  • 325289c7 e999 46d4 9191 0306c1f8dd64
    CEO

    Industry Pharmacist–. Corporate VP, Pharmaceutical Tech. for Biovail Corporation (now Valeant- North America) - – Senior VP Purgenesis (Canada) – Head R&D Galephar – Co-founder Trimel Pharma (TSX)
    More than 50 products on the market (17 in USA) . 32 granted patents in 19 families and 39 scientific papers

  • 2b823769 407d 4a51 beea 75e4026662d2
    CMO, BD, Corporate development

    MBA (Solvay Business School) - MD, Pathologist, Engineering –>20 years Pharma & Business
    CEO Imcyse– Octa-Pharma (Business Unit Manager) –Lambda plus (CMO)
    Previous Medical expert for Roche - Pfizer

  • E45ace21 c451 4c36 9280 06d3d508ff63
    Marketing - Corp. Development- BD

    Master Sciences VUB (Belgium) Post graduate Marketing (VUB) – MBA (Duke University)
    Global VP pulmonary Cipla and Teva – EU marketing Teva – General Manager GSK Belgium- VP marketing SMB
    Seasoned executive now strategy consultant.

  • 5bef67c4 686a 437b 9615 f3bd97b03cff
    PM- COO

    Ph. D in Pharmaceutical Sciences (2004)
    Experience at : L'Oréal, Barrier Therapeutics (JNJ) - Elysia
    Project Manager for the main project at Uteron Pharma (now Mithra)

Advisors

  • Default avatar
    Mosal
    Lawyer
    Unconfirmed
    Default avatar
    Peter Manso (Mintz IP)
    Unconfirmed